【摘要】 目的:了解硫酸亚铁控释片、琥珀酸亚铁、多糖铁复合物的成本效果情况.方法;将105例缺铁性贫血病人(男11例,女94例,年龄14～83岁),随机分入三个治疗组,分别予以硫酸亚铁控释片、琥珀酸亚铁、多糖铁复合物治疗8周,观察疗效并计算三药的费用效果情况.结果和结论:硫酸亚铁控释片、琥珀酸亚铁、多糖铁复合物三药的完全缓解率分别为76%、40%、74%,总的有效率分别为89%、76%、81%,三药中以多糖铁复合物的不良反应最少,硫酸亚铁控释片的不良反应最常见.进行费用效果分析,以完全缓解作为判断疗效的指标.发现琥珀酸亚铁具有良好的成本效果,多糖铁复合物最差.更多还原

【Abstract】 To identify the best iron preparations with good cost effectiveness for the treatment of iron deficiency anemia (IDA), 106 patients, including 11 males and 94 females with a mean age of 40.8 ± 12.6 year, were selected from the outpatient department. Those who had malignancies, connective tissue diseases , uncontrolled blood loss and those who had received iron preparations or blood transfusion were not included. The eligible patients were randomly diveded into 3 groups: Patients in Niferrix (polysaccharide-iron complex) group were given Niferrix at a dose of 0.15 g a day; patients in Ferroid (Ferrous sulfate controlled release tablets) received Ferroid at a dose of 0.5 g twice a day and patients in Ferrous succinate were given Ferrous succinate 0.1 g three times a day. Daily amount of iron element for each medicine was approximately similar. Patients were followed up every other week for 8 weeks for Hb level and SF. Complete remission rate (CR, with normal Hb level) was determined for each group. Cost was recorded during the follow-up. Our results showed that CRs in Niferrix, Ferroid and Ferrous succinate group were 0.4 (95% CI: 0.22-0.58), 0.74(0.58-0.90) and 0.76(0.6-0.92) respectively. Cost for Niferrix, Ferroid and Ferrous succinate groups were 2913. 8, 1527. 9 and 1332. 6 RMB Yuan respectively. The side effects of Ferroid was the highest and that of Niferrix was the lowest. Ferrous succinate showed the best cost-effectiveness. The Niferrix revealed the least cost-effectiveness.更多还原